Phase III data augur label expansion for Alexion's Ultomiris

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) plans to submit new data to regulatory authorities that could expand the label of long-acting complement 5 (C5) inhibitor Ultomiris ravulizumab-cwvz to

Read the full 269 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE